Meta-Analysis of the Association between Vitiligo and Human Leukocyte Antigen-A
Table 5
Association between vitiligo and human leukocyte antigen- (HLA-) A alleles in terms of typing methods.
Typing methods
Allele
Patients% ()
Controls% ()
OR (95% CI)/article number
Serological
A01
15.69 (91/580)
23.77 (444/1868)
0.95r (0.58, 1.56)/9
0.840
A02
55.92 (373/667)
44.21 (1377/3115)
1.64r (1.26, 2.13)/11
<0.001
A03
19.34 (118/610)
13.42 (322/2400)
1.58r (1.03, 2.42)/10
0.035
A04
3.85 (2/52)
3.00 (3/100)
1.29 (0.21, 7.99)/1
0.782
A09
20.07 (108/538)
26.25 (461/1756)
0.70 (0.54, 0.90)/8
0.005
A10
10.56 (47/445)
12.79 (175/1368)
1.11r (0.51, 2.41)/7
0.786
A11
17.99 (93/517)
14.61 (294/2012)
0.95 (0.71, 1.28)/9
0.751
A19
22.50 (18/80)
43.75 (35/80)
0.19r (0.02, 2.02)/2
0.170
A23
2.35 (2/85)
4.00 (8/200)
0.72 (0.17, 3.11)/2
0.662
A24
25.00 (31/124)
48.12 (358/744)
0.79r (0.17, 3.76)/3
0.767
A25
3.85 (2/52)
2.00 (2/100)
1.96 (0.27, 14.33)/1
0.507
A26
10.48 (13/124)
18.28 (136/744)
0.71 (0.38, 1.32)/3
0.282
A28
7.89 (31/393)
8.60 (109/1268)
0.74 (0.46, 1.17)/6
0.192
A29
4.94 (12/243)
7.34 (89/1212)
0.78 (0.42, 1.44)/5
0.434
A30
9.20 (24/261)
5.61 (63/1123)
1.55r (0.48, 5.03)/5
0.468
A31
14.26 (15/105)
8.28 (90/1087)
2.26 (1.22, 4.19)/3
0.009
A32
9.32 (11/118)
8.24 (53/643)
1.11 (0.55, 2.25)/3
0.774
A33
3.03 (2/66)
2.58 (14/543)
1.23 (0.32, 4.77)/2
0.763
A36
5.00 (2/40)
0.00 (0/40)
5.26 (0.24, 113.11)/1
0.289
A38
0.00 (0/40)
2.50 (1/40)
0.33 (0.01, 8.22)/1
0.495
A43
5.00 (2/40)
0.00 (0/40)
5.26 (0.24, 113.11)/1
0.289
A66
0.00 (0/52)
2.00 (2/100)
0.38 (0.02, 7.96)/1
0.529
A68
5.88 (5/85)
2.50 (5/200)
2.36 (0.67, 8.40)/2
0.317
A80
5.00 (2/40)
10.00 (4/40)
0.47 (0.08, 2.75)/1
0.405
Aw19
0.00 (0/48)
0.93 (1/107)
0.73 (0.03, 18.29)/1
0.849
Aw23
2.08 (1/48)
4.67 (5/107)
0.43 (0.05, 3.82)/1
0.452
Aw24
0.00 (0/48)
2.80 (3/107)
0.31 (0.02, 6.08)/1
0.439
Aw30
20.83 (10/48)
28.04 (30/107)
0.68 (0.30, 1.52)/1
0.345
Aw31
16.67 (8/48)
4.67 (5/107)
4.08 (1.26, 13.22)/1
0.019
Aw32
4.17 (2/48)
8.41 (9/107)
0.47 (0.10, 2.28)/1
0.351
Aw33
9.20 (8/87)
12.29 (80/651)
1.03 (0.46, 2.30)/2
0.944
Molecular
A01
52.15 (158/303)
47.07 (233/495)
0.94 (0.66, 1.33)/2
0.714
A02
17.98 (388/2158)
17.74 (333/1877)
1.31r (0.84, 2.05)/4
0.238
A03
21.55 (25/116)
23.05 (56/243)
0.92 (0.54, 1.56)/1
0.752
A11
6.03 (7/116)
12.76 (31/243)
0.44 (0.19, 1.03)/1
0.058
A23
7.76 (9/116)
9.88 (24/243)
0.77 (0.34, 1.71)/1
0.517
A24
18.10 (21/116)
17.28 (42/243)
1.06 (0.59, 1.89)/1
0.849
A25
13.20 (40/303)
6.46 (32/495)
0.71r (0.03, 19.23)/2
0.839
A26
7.91 (163/2061)
11.41 (206/1805)
0.83r (0.50, 1.38)/3
0.479
A29
8.62 (10/116)
10.70 (26/243)
0.79 (0.37, 1.69)/1
0.540
A30
14.84 (50/337)
9.38 (56/597)
2.22r (0.72, 6.83)/3
0.166
A31
3.35 (69/2061)
5.48 (99/1805)
0.68r (0.30, 1.55)/3
0.360
A32
3.45 (4/116)
8.23 (20/243)
0.40 (0.13, 1.19)/1
0.100
A33
22.84 (428/1874)
10.95 (170/1553)
1.56r (0.58, 4.24)/2
0.379
A34
0.00 (0/116)
3.29 (8/243)
0.12 (0.01, 2.08)/1
0.145
A36
0.00 (0/303)
2.42 (12/495)
0.12 (0.02, 0.91)/2
0.040
A43
37.43 (70/187)
42.46 (107/252)
0.81 (0.55, 1.19)/1
0.289
A66
3.30 (10/303)
8.89 (44/495)
0.70r (0.05, 10.81)/2
0.798
A68
14.83 (278/1874)
13.33 (207/1553)
1.27r (0.76, 2.13)/2
0.363
A69
0.00 (0/116)
0.82 (2/243)
0.41 (0.02, 8.71)/1
0.571
A80
0.00 (0/116)
0.41 (1/243)
0.69 (0.03, 17.16)/1
0.823
Aw19
0.74 (13/1758)
6.79 (89/1310)
0.10 (0.06, 0.18)/1
<0.001
: total number of subjects, : positive number of subjects, OR: odds ratio, CI: confidence interval, article number: total number of the articles relevant to the association between vitiligo and HLA-A alleles, r: random effects model, and the others: fixed effects model.
